Company intelligence / Profile preview
OBI Pharma
Nangang District, Taipei City, Taiwanobipharma.com ↗
- Ownership
- Private
- Employees
- ~140
- Development stage
- Other
01
Overview
OBI Pharma has advanced a robust pipeline of antibody-drug conjugates targeting cancer. Its lead program, OBI‑992, a TROP2-targeted ADC with a topoisomerase I inhibitor payload, has entered Phase I/II trials in the US and Taiwan with no dose-limiting toxicities observed to date. The company’s next-generation ADCs leverage proprietary platforms such as GlycOBI®, HYPrOBI™, and ThiOBI®. Another candidate, OBI‑902—a novel Trop‑2 ADC—received FDA IND clearance in April/May 2025 to begin clinical trials. Preclinical data show enhanced stability and efficacy compared to existing Trop‑2 ADCs[6][7][10]. Additional programs include small-molecule prodrugs like OBI‑3424 for HCC and ALL.
- Therapeutic areas
- Oncology
- Modalities
- Antibody-drug conjugates (ADCs)Small molecule prodrugs (e.g., AKR1C3-targeted prodrug)Active immunotherapies/vaccines
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
Collaborations with Ascentawits* and SWOG Cancer Research Network on clinical trialslicensing agreement with OBIGEN Pharma Biotech for global rights to certain assets[10][3].
Beyond the preview
Go deeper on OBI Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OBI Pharma.